共 50 条
Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation
被引:53
|作者:
Andrews, Peter A.
[1
]
Emery, Vincent C.
[2
]
Newstead, Chas
[3
]
机构:
[1] St Helier Hosp, Dept Nephrol, SW Thames Renal & Transplantat Unit, Carshalton SM5 1AA, Surrey, England
[2] UCL Med Sch, Dept Virol, London, England
[3] St James Univ Hosp, Dept Nephrol, Leeds, W Yorkshire, England
关键词:
Cytomegalovirus;
Guideline;
Transplantation;
Valganciclovir;
REPLACE PREEMPTIVE THERAPY;
CYTOMEGALOVIRUS DISEASE;
ORAL GANCICLOVIR;
RISK-FACTORS;
LEFLUNOMIDE FAILURE;
PROPHYLAXIS;
VALGANCICLOVIR;
RECIPIENTS;
INFECTION;
KIDNEY;
D O I:
10.1097/TP.0b013e318235c7fc
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
The third edition of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease after Solid Organ Transplantation was published in March 2011. This article summarizes the important changes and advances in management in this rapidly evolving field. The pros and cons of universal, or targeted anti-cytomegalovirus (CMV) prophylaxis, and pre-emptive anti-CMV therapy are discussed, especially with respect to advances in CMV polymerase chain reaction monitoring. The evidence for oral anti-CMV prophylaxis using valganciclovir is presented, together with a summary of the treatment of CMV disease and emerging fields such as CMV vaccination, CMV genotyping, and drug resistance.
引用
收藏
页码:1181 / 1187
页数:7
相关论文